WHAT IS metoject® PEN?
metoject® PEN is a pre-filled autoinjector containing the drug methotrexate. metoject® PEN is registered for the treatment of active rheumatoid arthritis and other autoimmune diseases. metoject® PEN is available in different doses. Your doctor will choose the correct dose for you.
HOW IS metoject® PEN TAKEN?
metoject® PEN is a ready to use autoinjector. The methotrexate solution in the pen is injected subcutaneously (under the skin). The drug is taken up without passing the digestive tract.
Please note that metoject® PEN has to be taken only once a week on the same day. Download information sheet: A4 Instruction guide
TRAVELLING WITH metoject® PEN
What should you consider
Please carry metoject® PEN / metex® PEN in the closed original packaging in your hand luggage. Hereby, you can control the storage at room temperature of > 15°C and < 25°C. Should the temperature rise above 25°C in the aircraft cabin, please ask a stewardess to put the pens in a fridge on board.
If you plan to travel to warmer areas, please consider to carry a small cooling box for the transport from the airport to your hotel. In case of unexpected elongation of your journey, please consider to take additional metoject® PENs with you.
Should you require any document to attest that you need metoject® PEN for your therapy when entering a foreign country, please find attached a certificate in English, Spanish, French, German and Turkish below. A completely filled out form should be accepted in most countries. Traveller's certificate for patients carrying metoject® PEN on flights: [Download PDF-File]
WHAT IS METHOTREXATE?
The active ingredient of metoject® 50 mg/ml is methotrexate (MTX). Methotrexate is a very well-known so-called disease modifying antirheumatic drug (DMARD) meaning that it does not just relieve the pain of patients with joint inflammation and/or psoriasis, but actually helps to stop and prevent this inflammation and the resulting damage. In these autoimmune diseases the immune system is too active and mistakenly attacks the own body. Methotrexate can help to slow down the effects of an over-stimulated immune system and thus to control disease activity.
In rheumatoid arthritis - and in some countries also in juvenile idiopathic arthritis, and psoriatic arthritis - methotrexate is the most commonly prescribed drug and is well-known also in the treatment of severe psoriasis.
Like any other medication, methotrexate can possibly be accompanied by side effects. Due to the relatively low doses of methotrexate used for the treatment of the diseases for which metoject® 50 mg/ml is indicated, these effects occur less often and are less severe than in the treatment with higher doses. Furthermore, there are several possibilities to reduce these discomforts. Therefore, should you have any side effect while taking the drug, please inform your doctor.